Chimerix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 07:37 am EDT
Share
Chimerix, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 31.97 million. Revenue was USD 32.56 million compared to USD 0.107 million a year ago. Net income was USD 241.36 million compared to net loss of USD 18.56 million a year ago. Basic earnings per share from continuing operations was USD 2.75 compared to basic loss per share from continuing operations of USD 0.21 a year ago. Diluted earnings per share from continuing operations was USD 2.75 compared to diluted loss per share from continuing operations of USD 0.21 a year ago.
For the nine months, sales was USD 31.97 million. Revenue was USD 33.01 million compared to USD 1.93 million a year ago. Net income was USD 193.13 million compared to net loss of USD 133.74 million a year ago. Basic earnings per share from continuing operations was USD 2.21 compared to basic loss per share from continuing operations of USD 1.59 a year ago. Diluted earnings per share from continuing operations was USD 2.17 compared to diluted loss per share from continuing operations of USD 1.59 a year ago.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with tunable specificity and modality, which enables therapeutic use for cancer and other diseases. Its ONC206 is an imipridone, Dopamine Receptor D2 (DRD2) antagonist and ClpP agonist. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
CHIMERIX, INC. 
